Industry Outlook 1999/Fund Managers
Executive Summary
Are small-cap stocks stuck in a temporary down cycle? Or are they being hurt by structural changes in the investment community? True, investment funds have increased in size to such a degree that it has become financially impossible for most of them to invest in small cap companies. But small companies have things that large companies don't--innovative and differentiable products that are so crucial to the growth of large companies. {IN VIVO} talks with top-ranked health care analyst Dan LeMaitre of Cowen & Co. about the pressures on large and small device companies.
You may also be interested in...
Pipeline Watch: Japan Dominates 25 New Approvals, Plus Six Phase III Updates
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
What’s Next? Five Things To Look Out For In October
A busy October will include planned biosimilar launches and key appointments for the off-patent sector.
Sandoz: Big Cap Biosimilar Rivals Lack Clarity On Commitment
Sandoz has had its say on its biosimilar rivals with largely branded portfolios, as well as the recent EMA statement supporting biosimilar interchangeability.